[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4MfMZKJOqHZAQKKx8PBZWKDBSdwelcKqdE1v8deY-I0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":40,"rows":47},"Boston University Charles River Campus",[4],137,false,32,3,16589,1,127,[14,17,19,21,24,26,29,32],{"name":15,"count":16},"Parkinson Disease",7,{"name":18,"count":16},"Stroke",{"name":20,"count":16},"Anxiety Disorders",{"name":22,"count":23},"Depression",6,{"name":25,"count":23},"Anxiety",{"name":27,"count":28},"Knee Osteoarthritis",5,{"name":30,"count":31},"Schizophrenia",4,{"name":33,"count":31},"Schizoaffective Disorder",[35],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05683223","Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety","2027-04-01","Sertraline",[41,42,43,44,45,46],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[48,72,163,181,206,224,251,269],{"intervention":39,"totalTrials":11,"cells":49},{"EARLY_PHASE1":50,"PHASE1":53,"PHASE2":55,"PHASE3":57,"PHASE4":59,"NA":61},{"trials":51,"activeCount":52},[],0,{"trials":54,"activeCount":52},[],{"trials":56,"activeCount":52},[],{"trials":58,"activeCount":52},[],{"trials":60,"activeCount":52},[],{"trials":62,"activeCount":11,"soonestReadout":38},[63],{"nctId":36,"briefTitle":37,"status":64,"phases":65,"primaryCompletion":38,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":71},"RECRUITING",[46],"2027-06-30","2023-05-26",240,[70],"Social Anxiety Disorder",[39],{"intervention":73,"totalTrials":16,"cells":74},"D-cycloserine",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":137,"PHASE4":159,"NA":161},{"trials":76,"activeCount":52},[],{"trials":78,"activeCount":52},[],{"trials":80,"activeCount":52},[81,93,102,114,126],{"nctId":82,"briefTitle":83,"status":84,"phases":85,"primaryCompletion":86,"completion":86,"start":87,"enrollment":52,"conditions":88,"interventions":90},"NCT04035603","Multimodal Cue Exposure Therapy for Smoking Cessation","WITHDRAWN",[43],"2021-01-31","2020-10-01",[89],"Smoking Cessation",[91,92],"D-Cycloserine","Open phase smoking cessation pharmacotherapy that proceeds the randomization phase",{"nctId":94,"briefTitle":95,"status":84,"phases":96,"primaryCompletion":97,"completion":97,"start":98,"enrollment":52,"conditions":99,"interventions":101},"NCT00827281","D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)",[43],"2015-07-15","2008-08",[100],"Smokers",[73],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT02983734","D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)","UNKNOWN",[43],"2019-09","2015-10",56,[111],"Gulf War Illness",[73,113],"Placebos",{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT00790868","Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder","COMPLETED",[43],"2014-08","2008-04",180,[123],"Panic Disorder",[125],"d-cycloserine",{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT00430573","Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use","TERMINATED",[43],"2009-06","2007-02",15,[135],"Substance-Related Disorders",[73],{"trials":138,"activeCount":52},[139,150],{"nctId":140,"briefTitle":141,"status":84,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":52,"conditions":146,"interventions":148},"NCT03216356","Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD",[43,44],"2023-12","2024-12","2016-09",[147],"PTSD",[91,149],"Study Pill",{"nctId":151,"briefTitle":152,"status":117,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT00515879","Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia",[44],"2011-12","2007-12",169,[70],[73],{"trials":160,"activeCount":52},[],{"trials":162,"activeCount":52},[],{"intervention":149,"totalTrials":11,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":177,"NA":179},{"trials":166,"activeCount":52},[],{"trials":168,"activeCount":52},[],{"trials":170,"activeCount":52},[],{"trials":172,"activeCount":52},[173],{"nctId":140,"briefTitle":141,"status":84,"phases":174,"primaryCompletion":143,"completion":144,"start":145,"enrollment":52,"conditions":175,"interventions":176},[43,44],[147],[91,149],{"trials":178,"activeCount":52},[],{"trials":180,"activeCount":52},[],{"intervention":182,"totalTrials":11,"cells":183},"Zonisamide",{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":202,"NA":204},{"trials":185,"activeCount":52},[],{"trials":187,"activeCount":52},[],{"trials":189,"activeCount":52},[],{"trials":191,"activeCount":52},[192],{"nctId":193,"briefTitle":194,"status":117,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT02901041","Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism",[44],"2022-01-04","2017-09-21",81,[200],"Alcohol Dependence",[182],{"trials":203,"activeCount":52},[],{"trials":205,"activeCount":52},[],{"intervention":92,"totalTrials":11,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":218,"PHASE4":220,"NA":222},{"trials":209,"activeCount":52},[],{"trials":211,"activeCount":52},[],{"trials":213,"activeCount":52},[214],{"nctId":82,"briefTitle":83,"status":84,"phases":215,"primaryCompletion":86,"completion":86,"start":87,"enrollment":52,"conditions":216,"interventions":217},[43],[89],[91,92],{"trials":219,"activeCount":52},[],{"trials":221,"activeCount":52},[],{"trials":223,"activeCount":52},[],{"intervention":225,"totalTrials":11,"cells":226},"250 mg DCS",{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":245,"PHASE4":247,"NA":249},{"trials":228,"activeCount":52},[],{"trials":230,"activeCount":52},[],{"trials":232,"activeCount":52},[233],{"nctId":234,"briefTitle":235,"status":117,"phases":236,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT02376257","Improving Therapeutic Learning in Depression: Proof of Concept",[43],"2017-04-21","2017-05","2014-09-16",36,[242],"Major Depressive Disorder",[225,244],"100 mg Modafinil",{"trials":246,"activeCount":52},[],{"trials":248,"activeCount":52},[],{"trials":250,"activeCount":52},[],{"intervention":244,"totalTrials":11,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":263,"PHASE4":265,"NA":267},{"trials":254,"activeCount":52},[],{"trials":256,"activeCount":52},[],{"trials":258,"activeCount":52},[259],{"nctId":234,"briefTitle":235,"status":117,"phases":260,"primaryCompletion":237,"completion":238,"start":239,"enrollment":240,"conditions":261,"interventions":262},[43],[242],[225,244],{"trials":264,"activeCount":52},[],{"trials":266,"activeCount":52},[],{"trials":268,"activeCount":52},[],{"intervention":113,"totalTrials":11,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":272,"activeCount":52},[],{"trials":274,"activeCount":52},[],{"trials":276,"activeCount":52},[277],{"nctId":103,"briefTitle":104,"status":105,"phases":278,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":279,"interventions":280},[43],[111],[73,113],{"trials":282,"activeCount":52},[],{"trials":284,"activeCount":52},[],{"trials":286,"activeCount":52},[]]